20n Bio
Latest round
- Seed
Last raised
- Dec 2021
Total raised
- $3.3M
Investors
- 1
About 20n Bio
20n Bio Inc.Founded in 2021 in the US, 20n Bio Inc. specializes in the discovery and development of cyclic peptides.20n Bio specializes in the discovery and development of cyclic peptides for therapeutic use, leveraging a proprietary high-throughput screening platform that can evaluate trillions of peptides simultaneously. This technology facilitates the identification of high-affinity peptides with optimal therapeutic properties, which can be utilized in various modalities such as oral peptides, radioligand therapy, and peptide-drug conjugates. The company aims to address significant unmet medical needs across multiple therapeutic areas, including metabolic disorders and complex cancers, by providing innovative peptide drugs that target diverse biological pathways. 20n Bio's clients include pharmaceutical and biotechnology companies with which they partner through licensing agreements for early-stage peptide candidates and customized solutions, thereby enhancing the drug development process.20n Bio generates revenue through strategic partnerships and licensing agreements with pharmaceutical and biotechnology firms, facilitating the development and commercialization of novel peptide therapeutics. Transactions typically occur through B2B agreements where clients license early peptide candidates that emerge from 20n Bio's high-throughput discovery platform. The company offers tailored solutions to assist partners in bringing these therapeutics to market efficiently, which can involve milestone payments and royalties based on the success of the developed products. Their revenue structure may include various collaboration frameworks, though specific pricing plans and financial terms related to individual services or products are not publicly disclosed.3 mn in December 2021, 20n Bio plans to expand its scientific team and establish a robust discovery platform. The company aims to enhance its product offerings and accelerate the development of its peptide therapeutics, thereby solidifying its position in the biotechnology sector.
Who invested in 20n Bio
1 investor across 1 round
See all investors in 20n Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Dec 17, 2021
Amount
$3.3M
Investors
Questions about 20n Bio
Who invested in 20n Bio?
20n Bio has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has 20n Bio raised?
20n Bio has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did 20n Bio last raise money?
20n Bio's most recent round on record is a Seed, in Dec 2021.
What does 20n Bio do?
20n Bio is a biotechnology company.
Where is 20n Bio headquartered?
20n Bio is headquartered in US.
Which VCs invest in companies like 20n Bio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at 20n Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like 20n Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.